EMA Authorised: Bevespi Aerosphere (glycopyrronium;formoterol fumarate dihydrate) — AstraZeneca AB

View source ↗

Summary

The European Medicines Agency authorised Bevespi Aerosphere, an inhaled fixed-dose combination of glycopyrronium and formoterol fumarate dihydrate, for chronic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Formoterol fumarate dihydrate
• glycopyrronium (glycopyrronium)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: AstraZeneca AB. Decision date: 02/12/2024